Bridge Biotherapeutics currently have two NCEs, BBT-401 and BBT-877 in development.

Program Indication 2017 2018 2019
BBT-401Pellino-1 Inhibitor Ulcerative Colitis 차트
BBT-877Autotaxin Inhibitor Idiopathic Pulmonary Fibrosis 차트
Next Generation
Development Stage 차트
New Project Development Stage 차트


BBT-401 is the first Pellino-1 inhibitor, which demonstrated to be highly selective and potent at industry standard preclinical models. BBT-401 has the first-in-class and the best-in-disease potential for the treatment of ulcerative colitis.

Indication / Disease more

- Ulcerative colitis

Target Protein

- Pellino-1

Development Stage

- US IND approved / Phase 1 clinical trial in progress
(Expected to be completed in 2018)

Unmet Medical Needs

- Poor patient compliance to first line therapies (5-ASA)

- Side-effects of second line treatment options (Steroids, Immunosuppressants)

- High price of third line treatment options (anti-TNF alpha and other biologics)

Differentiation Strategy and
Market Positioning

- Novel target (Pellino-1) inhibitor

- Confirmed excellent safety profiles Due to GI-tract restricted distribution

- Confirmed superior efficacy with anti-inflammatory and intestinal mucosa healing

Intellectual Property Rights

International patent applications and entries in 25 countries

Indication / Disease
팝업 이미지
Ulcerative Colitis, UC

Ulcerative colitis is a type of inflammatory bowel disease (IBD) that causes inflammation or ulceration in the mucosa or submucosa of large intestine. Unlike Crohn’s Disease (inflammatory bowel disease sporadically occurring in the small intestine and large intestine) which is another type of IBD, UC is characterized by lesions that start at the rectum adjacent to the anus and connect to the inside of the colon. Most patients with ulcerative colitis have dilute stool or diarrhea with blood and mucus several times a day. Some severe cases involve abdominal pain, dehydration, fever, vomiting and weight loss. Symptoms other than large intestine may include nodular erythema, gangrene pneumonia, and oral ulcers, which may include ophthalmic arthritis and ankylosing spondylitis. Most cases of ulcerative colitis are chronic recurring. Symptoms disappear in few weeks after occurrence, and they repeat again over a period of months to years. The more the recurrence, the worse the condition becomes, and overall, 3-18% of the patients are known to develop colon cancer. In addition, acute fulminant colitis is very symptomatic and may require surgery to remove the entire colon within a few days without response to treatment. As first-line drug, 5-ASA (mesalamine) may be prescribed, where steroids may be prescribed depending on the symptoms. Biological agents including immunosuppressants may also be used. The market is divided into high efficacy/high-priced biologic agents and low efficacy/safe first-line drug. There has been a constant need for a new first-line drug which demonstrate excellent efficacy but with reasonable price.



BBT-877 is potentially the best-in-class Autotaxin inhibitor for the treatment of various fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).

Indication / Disease more

- Idiopathic Pulmonary Fibrosis (IPF)

- Other fibrosis diseases such as NASH and certain types of cancers

Target Protein

- Autotaxin

Development Stage

- IND -enabling GLP tox (3 months away from US IND Submission)
- Expected to initiate US clinical trials in 2018

Unmet Medical Needs

- Narrow safety window of currently marketed drugs

- Improvement of lung function measured by FVC (forced vital capacity)

Differentiation Strategy and Market Positioning

- The best-in-class compound in Autotaxin space in terms of efficacy and safety profile

Intellectual Property Right

PCT application filed in 2018 (Korean patent granted)

Indication / Disease
팝업 이미지
Idiopathic Pulmonary Fibrosis, IPF

Idiopathic pulmonary fibrosis is a disease in which chronic inflammatory cells infiltrate the wall of the alveoli (pulmonary alveolus) without specific cause. Many changes which harden the lung, cause various structural changes in the lung tissue and gradually reduce the lung function, leading to death. Until now, there is no effective treatment method. Once the patient realize the symptoms and diagnosed with the disease, the average survival time is 3-5 years. The main symptoms are dry cough and dyspnea during workout which gradually progress over a period of 1-2 years. As IPF progresses, dyspnea gets worse, threatening daily life. When diagnosed, the rale from the bottom of the lung and clubbed finger are observed. At the terminal stage, symptoms such as dyspnea, liver hypertrophy, peripheral edema, anasarca are observed. It is known that about 50% of patients will die within 3-5 years as the symptoms continuously worsen and appropriate treatment is not made. IPF is a disease where early diagnosis and treatment are necessary. However, there is no special treatment other than delaying the symptoms. There is an urgent need for development of a treatment which will improve the symptoms of IPF.

    페이스북 트위터 링크드인

    HQ: Suite 903-2, Bldg B, Innovalley, 253 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13486 Republic of Korea
    US Office: Bridge Biotherapeutics, Inc. in JLABS@TMC, 2450 Holcombe Blvd. Houston, TX 77021, USA

    Director, Jong-jin Lim (jong-jin.lim@bridgebiorx.com)
    Manager, Joengbin Ahn (Joengbin.ahn@bridgebiorx.com)